
|Articles|April 14, 2020
Glaucoma 360: New developments in pharma (Ellie Chabi, MD; Santen, Inc)
Author(s)Alex Delaney-Gesing
Advertisement
Ellie Chabi, MD, therapeutic area head for Glaucoma & Neuroprotection, lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, shares insight on the company's role in the panel discussion focusing on new developments and discoveries in the glaucoma space during the 2020 Glaucoma 360 annual meeting in San Francisco, California.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
AAO 2025: A practice’s experience with connecting "the why," building community for techs
3
Ophthalmology over the decades: A catalyst of innovation in the 1970s
4
Ophthalmic innovation by the decades: The 1980s and 1990s
5